Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,626 | 211 | 1,384 |
| Samples | 769 | 135 | 618 |
| Peptides | 486 | 98 | 409 |
Function
GRM6 · Glutamate metabotropic receptor 6
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Mutations in this gene result in congenital stationary night blindness type 1B. [provided by RefSeq, May 2018].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 485 amino-acid changes on canonical ENST00000517717 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRM6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRM6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Melanoma | 12/210 6% | 92/1899 5% |
| Endometrial Carcinoma | 1/42 2% | 28/612 5% |
| Gastric Carcinoma | 12/74 16% | 58/1809 3% |
| Colorectal Carcinoma | 20/143 14% | 104/3239 3% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 39/1390 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Hodgkins Lymphoma | 1/16 6% | 3/122 2% |
| Other Solid Cancers | 1/94 1% | 45/1515 3% |
| Rhabdomyosarcoma | 1/33 3% | 3/171 2% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 13/810 2% |
| Non-Cancerous | 2/104 2% | 13/830 2% |
| Cervical Carcinoma | 1/35 3% | 6/422 1% |
| Esophageal Carcinoma | 0/23 0% | 12/769 2% |
| Bladder Carcinoma | 3/58 5% | 12/956 1% |
| Thyroid Gland Carcinoma | 3/45 7% | 20/1592 1% |
| Neuroendocrine Tumour | 6/154 4% | 4/577 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 10/752 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 29/2550 1% |
| Hepatocellular Carcinoma | 1/46 2% | 25/2210 1% |
| Biliary Tract Carcinoma | 1/54 2% | 10/950 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Pancreatic Carcinoma | 2/89 2% | 12/1611 1% |
| Head and Neck Carcinoma | 3/85 4% | 10/1574 1% |
| Prostate Carcinoma | 0/13 0% | 16/2105 1% |
Mutation Distribution
Where GRM6 is mutated · all tissues, split by cell line vs tissue
How many mutations in GRM6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,626 mutations in GRM6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|